Try our Advanced Search for more refined results

Deals Rumor Mill: Novartis, Disney, Shell

By Karlee Weinmann (April 14, 2014, 3:32 PM EDT) -- Several drugmakers are considering making bids for ThromboGenics NV, an European eye-medication company worth up to $1.3 billion, according to a Monday report from Bloomberg. Novartis AG, which is considered the front-runner, and Shire PLC are among the field of prospective bidders, along with Roche Holding AG, Valeant Pharmaceuticals International Inc. and Allergan Inc. Nonbinding offers are due at the end of the month. ThromboGenics shares have been on the rise since late February, when it said it had recruited Morgan Stanley to help it explore strategic options....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!